# Transcenta Holding

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/transcenta-holding

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.transcenta.com
- Total disclosed funding: $205M
- Latest round: Series B (Dec 23, 2020)
- Investors on record: 15

## About

Established in 2019 and based in Suzhou, China, Transcenta Holding Ltd. operates as a biopharmaceutical company that focuses on research, development, and manufacturing of biologics. The company is a merged entity of Hangzhou Just Biotherapeutics, Inc., an integrated design company focused on the technology of biotherapeutics from a molecule to a manufacturing plant, and MabSpace Biosciences Co., Ltd., a biotechnology company that focuses on the development of antibody-based therapeutics for the treatment of cancer and fibrotic disorders affecting the lungs, kidneys, and liver. The company has product development center and production base in Hangzhou, and clinical development centers in Shanghai, Beijing and Boston, USA. At present, the company has raised more than USD 342 million.

The company has develops nine new drug molecules, covering oncology, orthopedics and kidney disease. It focuses on reduce the time from drug target to BLA and to apply high quality next-generation GMPs. The company established partnerships with Libang Pharmaceutical and other biotechnology companies using his clinical expertise in nephropathy to co-develop TST004 in China.

## Funding rounds

- Series B, Dec 23, 2020, $105M — Hong Shan, Qatar Investment Authority, Lilly Asia Ventures, China Merchants Capital, Teng Yue Partners, China Structural Reform Fund Co., Ltd., Shenzhen Country Garden Venture Capital Co., Ltd.
- Series B, Jan 8, 2020, $100M — ARCH Venture Partners, Hong Shan, Temasek Holdings, Lilly Asia Ventures, ChinaEquity Group, Fortune Capital, Hillhouse Investment, CR Capital, CCT Fund Management, Teng Yue Partners, Epiphron Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Hong Shan — Series B
- Temasek Holdings — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- ChinaEquity Group (https://capitalatlas.ai/funds/chinaequity-group) — Series B
- Fortune Capital — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series B
- CCT Fund Management — Series B
- Teng Yue Partners (https://capitalatlas.ai/funds/teng-yue-partners) — Series B
- Epiphron Capital — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B
- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series B
- China Structural Reform Fund Co., Ltd. — Series B
- Shenzhen Country Garden Venture Capital Co., Ltd. — Series B